

Table 1**Treatment options for HCV genotypes 1, 2 and 3**

HCV genotype	Drug treatment	Duration
Genotype 1		
Treatment naive (non-cirrhotic)	Sofosbuvir, ledipasvir	8 weeks
	Ombitasvir, paritaprevir, ritonavir, dasabuvir	12 weeks
	Sofosbuvir, daclatasvir	12 weeks
	Sofosbuvir, simeprevir	12 weeks
Treatment experienced (non-cirrhotic)	Sofosbuvir, ledipasvir	12 weeks
	Ombitasvir, paritaprevir, ritonavir, dasabuvir	12 weeks
	Sofosbuvir, daclatasvir	12 weeks
Cirrhotic irrespective of previous treatment	Sofosbuvir, ledipasvir +/- ribavarin	12 weeks
	Ombitasvir, paritaprevir, ritonavir,	12 weeks
	dasabuvir, ribavirin	
	Sofosbuvir, daclatasvir, ribavirin	12 weeks
Genotype 2		
Interferon eligible	PEG interferon alpha with ribavirin	16-24 weeks
Interferon ineligible or treatment experienced	Sofosbuvir, ribavirin	12 weeks
Genotype 3		
Low viral load, mild to moderate fibrosis	PEG interferon alpha, ribavirin	16-24 weeks
Non-cirrhotic*	Sofosbuvir, PEG interferon alpha, ribavirin	12 weeks
	Sofosbuvir, daclatasvir, ribavirin,	12 weeks
	Sofosbuvir, ledipasvir, ribavirin,	12 weeks
Cirrhotic*	Sofosbuvir, PEG interferon alpha, ribavirin	12 weeks
Cirrhotic interferon ineligible *	Sofosbuvir, daclatasvir, ribavirin	12 weeks
	Sofosbuvir, ledipasvir, ribavirin	12 weeks